Orchid Pharma Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Orchid Pharma Ltd filed with BSE on 24 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Orchid Pharma reported combined Q1 FY27 revenue of INR304 crores, up approximately 15% from INR263 crores a year earlier, with EBITDA improving to INR25 crores from INR10 crores in the year-ago quarter. Management attributed the improvement to gross margin recovery to about 33% and continued cost discipline, while noting the cephalosporin industry still faces overcapacity and competitive pricing. The company also gave updates on the 7-ACA and cefiderocol capital projects, the Exblifep licensing arrangement in Russia, and volume growth in Europe.
2 statements from this call are not shown because their supporting quotes could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Revenue from operations: INR304 crores (Q1 FY27)
p. 4
“Revenue from operations increased to INR304 crores in Q1 '27 from INR263 crores in corresponding quarter last year, representing growth of approximately 15%.”
Manish Dhanuka, page 4 of the filed PDF · View the filing
EBITDA: INR25 crores (Q1 FY27)
p. 4
“EBITDA improved to INR25 crores in Q1 of '27 compared with EBITDA of INR10 crores in Q1 of '26.”
Manish Dhanuka, page 4 of the filed PDF · View the filing
Combined gross margin: 33% (Q1 FY27)
p. 4
“Combined gross margin improved by approximately 3% points to 33% in Q1 '27 compared with approximately 30% in Q1 of '26.”
Manish Dhanuka, page 4 of the filed PDF · View the filing
Revenue from operations: INR1,233 crores (FY26)
p. 3
“On a restated, combined basis, revenue from operations was INR1,233 crores for financial year '26 compared with INR1,398 crores for the financial year '25.”
Manish Dhanuka, page 3 of the filed PDF · View the filing
Combined gross margin: 32% (FY26)
p. 3
“Consequently, combined gross margin moderated by approximately 4% to 32% in financial year '26 compared to approximately 36% in financial year '25.”
Manish Dhanuka, page 3 of the filed PDF · View the filing
Combined employee and other operating expenses: INR353 crores (FY26)
p. 4
“Combined employee and other operating expenses were broadly flat at INR353 crores in FY26 compared with approximately INR353 crores in FY25.”
Manish Dhanuka, page 4 of the filed PDF · View the filing
Exblifep Russia licensing arrangement value: USD178 million (10-year estimate)
p. 4
“In Russia, the estimated 10-year value of our licensing arrangement is approximately USD178 million.”
Manish Dhanuka, page 4 of the filed PDF · View the filing
AMS division EBITDA loss: INR50 lakhs (Q1 FY27)
p. 13
“About INR50 lakhs for this quarter.”
Manish Dhanuka, page 13 of the filed PDF · View the filing
AMS division revenue: INR5 crores (Q1 FY27)
p. 13
“It was a revenue for AMS was INR5 crores.”
Manish Dhanuka, page 13 of the filed PDF · View the filing
NP-NC segment sales: INR21 crores (Q1 FY27)
p. 18
“So, this quarter sales was INR21 crores, and we are working on a couple of molecules.”
Manish Dhanuka, page 18 of the filed PDF · View the filing
7-ACA project capex: INR750 crores
p. 8
“INR750 crores is for the 7-ACA project and USD20 million to USD25 million, I don't remember the crores amount we have disclosed, for the cefiderocol project.”
Mridul Dhanuka, page 8 of the filed PDF · View the filing
Weighted average 7-ACA price: USD60
p. 6
“The weighted average is about USD60.”
Mridul Dhanuka, page 6 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
7-ACA project commissioning and first commercial batch — commissioning and first commercial batch · March 2027
stated firmly by Manish Dhanuka
p. 5
“Finally, on the 7-ACA project, our objective remains unchanged, commissioning and the first commercial batch by March of '27.”
Manish Dhanuka, page 5 of the filed PDF · View the filing
Cefiderocol project commissioning — commissioning · December 2026
stated firmly by Manish Dhanuka
p. 5
“We target commissioning by December of '26, followed by validation and initial batches during January to March '27 period.”
Manish Dhanuka, page 5 of the filed PDF · View the filing
7-ACA facility utilization ramp-up — 80% to 100% utilization · end of first year
stated as an aspiration by Mridul Dhanuka
p. 6
“So, our ramp-up plan is to go to about 80% to 100% by the end of the first year.”
Mridul Dhanuka, page 6 of the filed PDF · View the filing
7-ACA in-house vs third-party sales split — 80% in-house, 20% third party
stated as an aspiration by Mridul Dhanuka
p. 6
“With respect to utilization, our long-term guidance on this is 80% in-house use and 20% selling to third party.”
Mridul Dhanuka, page 6 of the filed PDF · View the filing
PLI benefit entitlement — 2 years
stated conditionally by Manish Dhanuka
p. 14
“PLI, we'll probably be entitled for 2 years. Based on the current scenario, we'll be entitled for 2 years.”
Manish Dhanuka, page 14 of the filed PDF · View the filing
Cefepime-Enmetazobactam lifetime sales potential — USD1.1 billion to USD2 billion
stated as an aspiration by Mridul Dhanuka
p. 11
“our long-term guidance on this is remaining the USD1.1 billion to USD2 billion that we came up with in 2021.”
Mridul Dhanuka, page 11 of the filed PDF · View the filing
Russia registration and commercial launch timeline — registration dossier submission and launch · 1.5 to 2 years
stated conditionally by Mridul Dhanuka
p. 12
“registration dossier submission and launch would take about 1.5 to 2 years.”
Mridul Dhanuka, page 12 of the filed PDF · View the filing
WHO Prequalification (PQ) filing — WHO PQ · around 2 years after filing
stated conditionally by Manish Dhanuka
p. 12
“It takes 2 years, around 2 years.”
Manish Dhanuka, page 12 of the filed PDF · View the filing
US formulation strategy launch — US launch of new molecules · 2030
stated firmly by Mridul Dhanuka
p. 13
“we just talked about that strategy first time last quarter, and the guidance is still 2030.”
Mridul Dhanuka, page 13 of the filed PDF · View the filing
Zavicefta US filing — validation batches then filing · this year or early next year, plus six months
stated conditionally by Manish Dhanuka
p. 17
“I am hoping maybe validation batches maybe this year or early next year, and then six months for filing.”
Manish Dhanuka, page 17 of the filed PDF · View the filing
Integration savings from merger — initial benefits visible · next financial year
stated as an aspiration by Manish Dhanuka
p. 4
“We expect initial benefits of these initiatives to begin becoming visible in the next financial year.”
Manish Dhanuka, page 4 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said regulated market demand is cyclical and this quarter was mediocre, hoping for improvement in the next two-three quarters.
Answered by Manish Dhanuka
Asked by Shashwat Vijay: Will there be margin recovery in H2 or will it take until FY28 given industry pricing pressure?
p. 6
“So, it's very difficult to predict in that -- in that area. But for us, what is important is the regulated market demand, which also is kind of cyclical”
Manish Dhanuka, page 6 of the filed PDF · View the filing
Management said 7-ACA pricing has been stable for 10-12 years and does not expect drastic reductions.
Answered by Mridul Dhanuka
Asked by Tarun Krishna: Are Chinese 7-ACA exporters likely to drastically cut prices once Orchid's site is commissioned?
p. 6
“The pricing in 7-ACA has been stable over the last 10 to 12 years.”
Mridul Dhanuka, page 6 of the filed PDF · View the filing
Management said no significant new capex is planned beyond completing the cefiderocol and 7-ACA projects already underway.
Answered by Manish Dhanuka
Asked by Nishita: What capex is budgeted for FY27 given the new facilities?
p. 8
“So, as such -- we have not considered very significant capex in the next financial year. In this financial year, we will be completing our projects of cefiderocol and 7-ACA.”
Manish Dhanuka, page 8 of the filed PDF · View the filing
Management said the joint price coordination seen in Pen G never occurred in 7-ACA and prices have stayed stable, though outcomes remain unpredictable.
Answered by Mridul Dhanuka
Asked by Dhwanil Desai: Could China dump 7-ACA prices similar to what happened with Aurobindo's Pen G project?
p. 9
“in 7-ACA, that joint cooperation or whatever you want to call it was never happened, and the prices have been stable.”
Mridul Dhanuka, page 9 of the filed PDF · View the filing
Management pointed to the earlier waiver granted for Cefepime-Enmetazobactam as a precedent.
Answered by Manish Dhanuka
Asked by Rupesh Tatia: Is there precedent for DCGI granting a clinical trial waiver for cefiderocol?
p. 12
“Yeah, yeah, our Cefepime-Enmetazobactam itself is a precedent. We got the waiver because the committee thought that the -- because of the antimicrobial resistance, the country needs new antibiotics.”
Manish Dhanuka, page 12 of the filed PDF · View the filing
Management said 7-ACA pricing has been stable, but Cefixime is under maximum margin pressure due to rest-of-world volume competition.
Answered by Manish Dhanuka
Asked by Vishal Manchanda: Are there material price changes quarter-over-quarter for 7-ACA and final APIs like Cefixime and Cefuroxime?
p. 16
“Cefixime is the one having maximum pressure. Cefuroxime and other 7-ACA-based, fortunately, seem to be more stable compared to Cefixime.”
Manish Dhanuka, page 16 of the filed PDF · View the filing
Risks flagged
Cephalosporin industry overcapacity leading to intense competition
p. 4
“Though we can see some improvement in sales over last year, we feel the industry is still facing overcapacities leading to cutthroat competition.”
Manish Dhanuka, page 4 of the filed PDF · View the filing
Difficult pricing and volume environment for cephalosporin business in FY26
p. 3
“It was among the most challenging environments our cephalosporin franchise has faced in the last 15 to 20 years.”
Manish Dhanuka, page 3 of the filed PDF · View the filing
Middle East launch activity affected by regional conflict
p. 4
“Planned launch activity in the region has been affected by the recent regional conflict, and timing of commercial rollout will depend on normalization of conditions in the Middle East.”
Manish Dhanuka, page 4 of the filed PDF · View the filing
Equipment sourcing complexity for cefiderocol project due to rerouting from China through Italy
p. 4
“Some equipment originally sourced from China had to be rerouted through Italy. While this created execution complexity, it has not Orchid Pharma Limited August 21, 2026 Page 4 of 17 changed the overall project timelines.”
Manish Dhanuka, page 4 of the filed PDF · View the filing
Cefiderocol commercial launch depends on DCGI approval process
p. 5
“Commercial launch will be subject to the approval process from DCGI.”
Manish Dhanuka, page 5 of the filed PDF · View the filing
Fermentation scale-up for 7-ACA is unpredictable and could take longer than guided
p. 10
“It is something unpredictable, and we wait -- we'll have to wait to see what actually happens.”
Mridul Dhanuka, page 10 of the filed PDF · View the filing
Cefixime margins under maximum stress in rest-of-world markets
p. 16
“It's for the rest of the world market is where the volumes are huge and that's where the pressure comes from.”
Manish Dhanuka, page 16 of the filed PDF · View the filing
Unpredictability of Chinese manufacturer pricing behavior
p. 9
“But having said that, they are unpredictable. Sometimes other things can still happen.”
Mridul Dhanuka, page 9 of the filed PDF · View the filing
Zavicefta US filing previously faced objections
p. 17
“And the U.S. plan, although unfortunately last filing had some objections, we still continue to have plans to re-file, and that is going on.”
Manish Dhanuka, page 17 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.